Literature DB >> 7622186

Synergism of IL-3, IL-5, and GM-CSF on eosinophil differentiation and its application for an assay of murine IL-5 as an eosinophil differentiation factor.

M Takamoto1, K Sugane.   

Abstract

In order to elucidate the mechanisms of eosinophil differentiation, we examined the effects of combinations of interleukin 5 (IL-5) with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) on in vitro differentiation into eosinophils from bone marrow cells of ICR mice. When the amount of added IL-5 was kept constant, IL-3 exhibited dose-dependent production of eosinophils both in the absence and presence of low doses of GM-CSF. In contrast, IL-5 plus GM-CSF showed highly enhanced production of eosinophils, and eosinophil production maximized at a concentration between 10 and 20 U/ml and decreased at higher concentrations. When IL-3 and GM-CSF were kept constant at concentrations of 20 U/ml and 10 U/ml, respectively, the number of eosinophils increased linearly in IL-5-dependent manner in a range from 0.3 to 30 U/ml. These results suggest that IL-3 and GM-CSF act synergistically with IL-5 in in vitro eosinophil differentiation. In addition, we propose a new method for quantifying eosinophil differentiation activity of IL-5.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622186     DOI: 10.1016/0165-2478(94)00223-e

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

1.  Representational difference analysis of a committed myeloid progenitor cell line reveals evidence for bilineage potential.

Authors:  N D Lawson; N Berliner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

2.  Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow.

Authors:  Kimberly D Dyer; Jennifer M Moser; Meggan Czapiga; Steven J Siegel; Caroline M Percopo; Helene F Rosenberg
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

3.  JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.

Authors:  Ami B Patel; Anca Franzini; Emilie Leroy; Soo Jin Kim; Anthony D Pomicter; Lidvine Genet; Michael Xiao; Dongqing Yan; Jonathan M Ahmann; Archana M Agarwal; Phillip Clair; Juanah Addada; Jonathan Lambert; Matthew Salmon; Gerald J Gleich; Nicholas C P Cross; Stefan N Constantinescu; Thomas O'Hare; Josef T Prchal; Michael W Deininger
Journal:  Blood       Date:  2019-12-26       Impact factor: 25.476

4.  Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Authors:  Bart Hilvering; Timothy S C Hinks; Linda Stöger; Emanuele Marchi; Maryam Salimi; Rahul Shrimanker; Wei Liu; Wentao Chen; Jian Luo; Simei Go; Timothy Powell; Jennifer Cane; Samantha Thulborn; Ayako Kurioka; Tianqi Leng; Jamie Matthews; Clare Connolly; Catherine Borg; Mona Bafadhel; Christian B Willberg; Adaikalavan Ramasamy; Ratko Djukanović; Graham Ogg; Ian D Pavord; Paul Klenerman; Luzheng Xue
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

5.  Eosinophils Protect Mice From Angiotensin-II Perfusion-Induced Abdominal Aortic Aneurysm.

Authors:  Cong-Lin Liu; Xin Liu; Yuanyuan Zhang; Jing Liu; Chongzhe Yang; Songyuan Luo; Tianxiao Liu; Yunzhe Wang; Jes S Lindholt; Axel Diederichsen; Lars M Rasmussen; Marie Dahl; Galina K Sukhova; Guanyi Lu; Gilbert R Upchurch; Peter Libby; Junli Guo; Jinying Zhang; Guo-Ping Shi
Journal:  Circ Res       Date:  2020-11-06       Impact factor: 17.367

6.  Eosinophils in fungus-associated allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.